-
-
-
-
-
-
-
Kiora Pharmaceuticals (KPRX) Tops Q3 EPS by 1c
-
-
-
-
-
-
-
Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027
-
-
-
-
-
-
-
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases
-
-
-
-
-
-
-
Kiora Pharmaceuticals (KPRX) Reports FY21 Results, Provides Corporate Update
-
-
1,218,242 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

